Combinatorial treatment of mammospheres with trastuzumab and salinomycin efficiently targets HER2-positive cancer cells and cancer stem cells (Q39363067)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Combinatorial treatment of mammospheres with trastuzumab and salinomycin efficiently targets HER2-positive cancer cells and cancer stem cells	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

11 September 2017

Combinatorial treatment of mammospheres with trastuzumab and salinomycin efficiently targets HER2-positive cancer cells and cancer stem cells (English)

1 reference

Europe PubMed Central

11 September 2017

neoplastic stem cells

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

7

1 reference

Europe PubMed Central

11 September 2017

author name string

Prajakta S Oak

1

1 reference

Europe PubMed Central

11 September 2017

Florian Kopp

2

1 reference

Europe PubMed Central

11 September 2017

Chitra Thakur

3

1 reference

Europe PubMed Central

11 September 2017

Joachim W Ellwart

4

1 reference

Europe PubMed Central

11 September 2017

Ulf R Rapp

5

1 reference

Europe PubMed Central

11 September 2017

Axel Ullrich

6

1 reference

Europe PubMed Central

11 September 2017

Pjotr Knyazev

8

1 reference

Europe PubMed Central

11 September 2017

Andreas Roidl

9

1 reference

Europe PubMed Central

11 September 2017

language of work or name

0 references

publication date

21 May 2012

1 reference

Europe PubMed Central

11 September 2017

number of pages

12

1 reference

based on heuristic

inferred from page(s)

International Journal of Cancer

1 reference

Europe PubMed Central

11 September 2017

131

1 reference

Europe PubMed Central

11 September 2017

12

1 reference

Europe PubMed Central

11 September 2017

2808-2819

1 reference

Europe PubMed Central

11 September 2017

Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

Primary systemic therapy in operable breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

ABC multidrug transporters: structure, function and role in chemoresistance.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

Breast cancer chemoresistance: emerging importance of cancer stem cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

Tumour stem cells and drug resistance

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

Prospective identification of tumorigenic breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

Breast cancer stem cell markers - the rocky road to clinical applications

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

Generation of induced pluripotent stem cells using recombinant proteins

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

"Stemness" genomics law governs clinical behavior of human cancer: implications for decision making in disease management

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

Use of three-dimensional basement membrane cultures to model oncogene-induced changes in mammary epithelial morphogenesis

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

HER-2 testing in breast cancer using parallel tissue-based methods

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

Molecular mechanisms underlying ErbB2/HER2 action in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

The role of overexpressed HER2 in transformation

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

Human mammary progenitor cell fate decisions are products of interactions with combinatorial microenvironments

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

MYC is a metastasis gene for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

Identification of selective inhibitors of cancer stem cells by high-throughput screening

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

Cancer stem cells in solid tumours: accumulating evidence and unresolved questions

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

ERBB receptors and cancer: the complexity of targeted inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

ErbB2 requires integrin alpha5 for anoikis resistance via Src regulation of receptor activity in human mammary epithelial cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

Resistance to Trastuzumab in Breast Cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

Salinomycin Effects on Mitochondrial Ion Translocation and Respiration

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

Conformation and location of membrane-bound salinomycin-sodium complex deduced from NMR in isotropic bicelles.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

Salinomycin selectively targets 'CD133+' cell subpopulations and decreases malignant traits in colorectal cancer lines

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control

1 reference

https://api.crossref.org/works/10.1002%2FIJC.27595

21 January 2018

Identifiers

10.1002/IJC.27595

1 reference

Europe PubMed Central

11 September 2017

1 reference

Europe PubMed Central

11 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39363067&oldid=1823043485"